AC Immune Receives FDA Fast Track Designation for ACI-7104 in Parkinson’s
LAUSANNE, Switzerland, August 11, 2026 AC Immune SA announced that the U.S. Food and Drug Administration (FDA) has granted...
alpha-synuclein
Advertisement
Innogen Gains PIC/S GMP Certification for Efsubaglutide
Shanghai, China – August 4, 2026 Innogen Pharmaceuticals has announced that its Efsubaglutide alfa manufacturing facility in Suzhou has...
CND Life Sciences Secures Growth Funding for Syn-One Test
Scottsdale, Arizona & Boca Raton, Florida, August 4, 2026 CND Life Sciences has announced the successful completion of a...
Dyne Secures FDA IND Clearance for DYNE-302 in FSHD
Waltham, Massachusetts, July 28, 2026 Dyne Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has cleared...
Galmed Advances Brain-Targeted Aramchol for Parkinson’s
Ramat-Gan, Israel, July 28, 2026 Galmed Pharmaceuticals Ltd. has announced a significant advancement in the development of Aramchol orally...
Advertisements
Chiesi, Arbor Secure EU Orphan Status for ABO-101
PARMA, Italy & CAMBRIDGE, Mass., June 25, 2026 Chiesi Group and Arbor Biotechnologies have achieved a significant regulatory milestone...
Ionis Partners with Recordati to Expand Zilganersen Globally
CARLSBAD, Calif., June 25, 2026 Ionis Pharmaceuticals has entered into a landmark global licensing agreement with Recordati to accelerate...
Anivive Wins FDA Approval for First Oral Canine Lymphoma Drug
LONG BEACH, Calif., June 26, 2026 Anivive Lifesciences has achieved a landmark milestone after the U.S. Food and Drug...
NeuroSense PrimeC Shows Positive Phase 2 Alzheimer’s Biomarker Data
CAMBRIDGE, Mass., June 25, 2026 NeuroSense Therapeutics Ltd. announced positive biomarker findings from its Phase 2 randomized, double-blind, placebo-controlled...
Single-Molecule Proteomics Targets Alpha-Synuclein in Parkinson’s
January 28, 2026 — Nautilus Biotechnology, Weill Cornell Medicine–Qatar (WCM-Q), and The Michael J. Fox Foundation (MJFF) have launched...
Advertisement
